Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

NBJ pairs the latest data on the supplements and nutrition market with timely insights on how trends impact businesses today,' says Jessica Rubino, New Hope Network Vice President, Content and Summits ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains ... treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

GLP-1 receptor agonists, originally developed for managing type ... By reducing hunger and promoting a feeling of fullness, ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

By now, stories of people achieving their weight loss goals while taking Ozempic, Zepbound, or other GLP-1 receptor agonists abound—but that doesn’t mean everyone will shed pounds on these ...

A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...